<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38218668</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.</ArticleTitle><Pagination><StartPage>819</StartPage><EndPage>827</EndPage><MedlinePgn>819-827</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2023.12.081</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(23)01541-4</ELocationID><Abstract><AbstractText>Delays in achieving polio eradication have led to ongoing risks of poliovirus importations that may cause outbreaks in polio-free countries. Because of the low, but non-zero risk of paralysis with oral poliovirus vaccines (OPVs), countries that achieve and maintain high national routine immunization coverage have increasingly shifted to exclusive use of inactivated poliovirus vaccine (IPV) for all preventive immunizations. However, immunization coverage within countries varies, with under-vaccinated subpopulations potentially able to sustain transmission of imported polioviruses and experience local outbreaks. Due to its cost, ease-of-use, and ability to induce mucosal immunity, using OPV as an outbreak control measure offers a more cost-effective option in countries in which OPV remains in use. However, recent polio outbreaks in IPV-only countries raise questions about whether and when IPV use for outbreak response may fail to stop poliovirus transmission and what consequences may follow from using OPV for outbreak response in these countries. We systematically reviewed the literature to identify modeling studies that explored the use of IPV for outbreak response in IPV-only countries. In addition, applying a model of the 2022 type 2 poliovirus outbreak in New York, we characterized the implications of using different OPV formulations for outbreak response instead of IPV. We also explored the hypothetical scenario of the same outbreak except for type 1 poliovirus instead of type 2. We find that using IPV for outbreak response will likely only stop outbreaks for polioviruses of relatively low transmission potential in countries with very high overall immunization coverage, seasonal transmission dynamics, and only if IPV immunization interventions reach some unvaccinated individuals. Using OPV for outbreak response in IPV-only countries poses substantial risks and challenges that require careful consideration, but may represent an option to consider for some outbreaks in some populations depending on the properties of the available vaccines and coverage attainable.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA. Electronic address: kimt@kidrisk.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kidd</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NU2RGH001915</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073887" MajorTopicYN="N">Vaccination Coverage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dynamic modeling</Keyword><Keyword MajorTopicYN="N">Eradication</Keyword><Keyword MajorTopicYN="N">Outbreak response</Keyword><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kid Risk authors (KMT, DAK, KB) reports financial support was provided by Centers for Disease Control and Prevention. Kid Risk authors (KMT, DAK, KB) reports a relationship with Centers for Disease Control and Prevention that includes: funding grants.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>14</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>13</Day><Hour>21</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38218668</ArticleId><ArticleId IdType="mid">NIHMS1972228</ArticleId><ArticleId IdType="pmc">PMC10947589</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2023.12.081</ArticleId><ArticleId IdType="pii">S0264-410X(23)01541-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al., Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep 2022; 71(33):1065–1068 DOI: 10.15585/mmwr.mm7133e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7133e2</ArticleId><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Klapsa D, Wilton T, Zealand A, et al., Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet 2022; 400(10362):1531–8 DOI: 10.1016/S0140-6736(22)01804-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01804-9</ArticleId><ArticleId IdType="pmc">PMC9627700</ArticleId><ArticleId IdType="pubmed">36243024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman NS, Bar-Or I, Sofer D, et al., Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022. Euro Surveill 2022; 27(37):2200694 DOI: doi:10.2807/1560-7917.ES.2022.27.37.2200694.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.37.2200694</ArticleId><ArticleId IdType="pmc">PMC9479469</ArticleId><ArticleId IdType="pubmed">36111556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Health Organization. 2022. Epidemiological Update Detection of poliovirus in wastewater: Considerations for the Region of the Americas 30 December 2022.
Regional Office for the Americas of the World Health Organization (Accessed
Jan 10, 2023). Available from: https://www.paho.org/en/documents/epidemiological-update-detection-poliovirus-wastewater.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. 2022. Standard operating procedures: Responding to a poliovirus event or outbreak, Version 4.1
World Health Organization. (Accessed
Aug 2, 2023). Available from: https://polioeradication.org/wp-content/uploads/2022/09/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-Outbreak-20220905-V4-EN.pdf.</Citation></Reference><Reference><Citation>Bandyopadhyay AS, Cavestany RL, Blake IM, et al., Use of inactivated poliovirus vaccine for poliovirus outbreak response. Lancet Infect Dis 2023; DOI: 10.1016/S1473-3099(23)00505-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00505-4</ArticleId><ArticleId IdType="pubmed">38012892</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Wallace GS, Tebbens RJ, et al., Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep 2012; 127(1):23–37 DOI: 10.1177/003335491212700104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/003335491212700104</ArticleId><ArticleId IdType="pmc">PMC3234395</ArticleId><ArticleId IdType="pubmed">22298920</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Pallansch MA, Duintjer Tebbens RJ, et al., Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013; 33(4):647–63 DOI: 10.1111/j.1539-6924.2012.01891.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC7896539</ArticleId><ArticleId IdType="pubmed">22985171</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, Routh JA, et al., Modeling poliovirus transmission and responses in New York State. J Infect Dis 2023: DOI:10.1093/infdis/jiad355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad355</ArticleId><ArticleId IdType="pmc">PMC11284859</ArticleId><ArticleId IdType="pubmed">37596838</ArticleId></ArticleIdList></Reference><Reference><Citation>New York City Department of Health and Mental Hygiene.
2022. Polio. New York City Department of Health and Mental Hygiene (Accessed
Jan 3, 2023). Available from: https://www.nyc.gov/site/doh/health/health-topics/poliomyelitis.page.</Citation></Reference><Reference><Citation>New York State Department of Health. Polio
2022. (Accessed
3 Jan). Available from: https://www.health.ny.gov/diseases/communicable/polio/.</Citation></Reference><Reference><Citation>Ryerson AB, Lang D, Alazawi MA, et al., Wastewater Testing and Detection of Poliovirus Type 2 Genetically Linked to Virus Isolated from a Paralytic Polio Case - New York, March 9-October 11, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(44):1418–1424 DOI: 10.15585/mmwr.mm7144e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144e2</ArticleId><ArticleId IdType="pmc">PMC9639435</ArticleId><ArticleId IdType="pubmed">36327157</ArticleId></ArticleIdList></Reference><Reference><Citation>Estivariz CF, Kovacs SD, and Mach O, Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks. Vaccine 2023; 41(Suppl 1):A113–A121 DOI: 10.1016/j.vaccine.2022.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.027</ArticleId><ArticleId IdType="pmc">PMC10389290</ArticleId><ArticleId IdType="pubmed">35365341</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins PC and Modlin JF, Decision analysis in planning for a polio outbreak in the United States. Pediatrics 2006; 118(2):611–8 DOI: 10.1542/peds.2005-2358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2005-2358</ArticleId><ArticleId IdType="pubmed">16882814</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Badizadegan K, A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States. Risk Anal 2021; 41(2):376–386 DOI: 10.1111/risa.13614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13614</ArticleId><ArticleId IdType="pmc">PMC7983986</ArticleId><ArticleId IdType="pubmed">33084153</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, Peak C, Eisenhawer M, et al., Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine 2023; 41 Suppl 1(Suppl 1):A122–A127 DOI: 10.1016/j.vaccine.2022.02.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill M, Bandyopadhyay AS, and Pollard AJ, Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use. Lancet 2022; 400(10354):713–715 DOI: 10.1016/s0140-6736(22)01582-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(22)01582-3</ArticleId><ArticleId IdType="pubmed">35988575</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al., Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006; 26(6):1471–505 DOI: 10.1111/j.1539-6924.2006.00827.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2006.00827.x</ArticleId><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Polio vaccines: WHO position paper - June 2022. Wkly Epidemiol Rec 2022; 97(25):277–300.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al., Expert review on poliovirus immunity and transmission. Risk Anal 2013; 33(4):544–605 DOI: 10.1111/j.1539-6924.2012.01864.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2012.01864.x</ArticleId><ArticleId IdType="pmc">PMC7896540</ArticleId><ArticleId IdType="pubmed">22804479</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al., Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013; 33(4):606–46 DOI: 10.1111/risa.12031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12031</ArticleId><ArticleId IdType="pmc">PMC7890644</ArticleId><ArticleId IdType="pubmed">23550968</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al., Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013; 33(4):680–702 DOI: 10.1111/risa.12022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12022</ArticleId><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. 2023. GPEI Statement on cVDPV2 detections in Burundi and Democratic Republic of the Congo
World Health Organization. (Accessed
June 27, 2023). Available from: https://polioeradication.org/news-post/gpei-statement-on-cvdpv2-detections-in-burundi-and-democratic-republic-of-the-congo/.</Citation></Reference><Reference><Citation>Yeh MT, Smith M, Carlyle S, et al., Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature 2023; DOI: 10.1038/s41586-023-06212-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06212-3</ArticleId><ArticleId IdType="pmc">PMC10322712</ArticleId><ArticleId IdType="pubmed">37316671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Wiesen E, et al., Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation [version 1; peer review: 1 approved]. Gates Open Res 2023; 7:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10403636</ArticleId><ArticleId IdType="pubmed">37547300</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Sutter RW, and Oostvogel PM, Outbreaks of paralytic poliomyelitis, 1976–1995. J Infect Dis 1997; 175(Suppl 1):S165–72 DOI: 10.1093/infdis/175.supplement_1.s165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/175.supplement_1.s165</ArticleId><ArticleId IdType="pubmed">9203711</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N and Kew OM, From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epi 2010; 172(11):1213–1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991634</ArticleId><ArticleId IdType="pubmed">20978089</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al., Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013; 33(4):703–49 DOI: 10.1111/risa.12044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12044</ArticleId><ArticleId IdType="pubmed">23521018</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. 2023. Circulating vaccine-derived poliovirus (as of 8 Aug 2023).
World Health Organization - Global Polio Eradication Initiative
(Accessed
August 15, 2023). Available from: https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/.</Citation></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, and Thompson KM, Outbreak management strategies for cocirculation of multiple poliovirus types. Vaccine 2023; DOI: 10.1016/j.vaccine.2023.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.04.037</ArticleId><ArticleId IdType="pubmed">37121801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Wiesen E, et al., Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Risk Anal 2023; DOI: 10.1111/risa.14158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.14158</ArticleId><ArticleId IdType="pmc">PMC10733544</ArticleId><ArticleId IdType="pubmed">37344934</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kassab-Cordova A, Napanga-Saldana O, Pena-Sanchez R, et al., Vaccine-derived polio in Peru after 32 years of elimination: reflections on the routine childhood immunisation coverages. Lancet Reg Health Am 2023; 23:100532 DOI: 10.1016/j.lana.2023.100532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100532</ArticleId><ArticleId IdType="pmc">PMC10279534</ArticleId><ArticleId IdType="pubmed">37346381</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 2006; 26(6):1423–40 DOI: 10.1111/j.1539-6924.2006.00831.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2006.00831.x</ArticleId><ArticleId IdType="pubmed">17184390</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Badizadegan K, Oral polio vaccine stockpile modeling: insights from recent experience. Expert Rev Vaccines 2023; 22(1):813–825 DOI: 10.1080/14760584.2023.2263096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2263096</ArticleId><ArticleId IdType="pubmed">37747090</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. 2017. Standard operating procedures: Responding to a poliovirus event or outbreak, Version 2.4 Part 1: General SOPs
World Health Organization. (Accessed
Aug 2, 2023). Available from: https://www.medbox.org/document/responding-to-a-poliovirus-event-or-outbreak-part-1-general-sops#GO.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. 2017. Standard operating procedures: Responding to a poliovirus event or outbreak, Version 2.4 Part 2: Protocol for poliovirus type 2
World Health Organization. (Accessed
Aug 2, 2023). Available from: http://polioeradication.org/wp-content/uploads/2018/01/pol-sop-responding-polio-event-outbreak-part2-20180117.pdf.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. 2020. Standard operating procedures: Responding to a poliovirus event or outbreak, Version 3.1
World Health Organization. (Accessed
Aug 2, 2023). Available from: https://apps.who.int/iris/handle/10665/331895.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. 2015. Responding to a poliovirus outbreak: Standard operating procedures for a new polio outbreak in a polio-free country
World Health Organization. (Accessed
15 March 2015). Available from: http://www.polioeradication.org/Portals/0/Document/Resources/PolioEradicators/1a.PolioOutbreakGuideline20150220.pdf.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. 2015. Protocol for notification, risk assessment, and response following detection of poliovirus type 2 following globallycoordinated cessation of serotype 2-containing oral polio vaccine
World Health Organization. (Accessed
Aug 2, 2023). Available from: https://www3.paho.org/hq/dmdocuments/2015/Poliovirus-type2-response-protocol-eng.pdf.</Citation></Reference><Reference><Citation>Thompson KM and Kalkowska DA, Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Rev Vaccines 2020:1–25 DOI: 10.1080/14760584.2020.1791093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2020.1791093</ArticleId><ArticleId IdType="pmc">PMC7497282</ArticleId><ArticleId IdType="pubmed">32741232</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. 2023. nOPV2: Clinical Development and Evidence Summary. World Health Organization - Global Polio Eradication Initiative
(Accessed
4 July 2023). Available from: https://polioeradication.org/wp-content/uploads/2023/05/EN_nOPV2-Clinical-Development-Summary_Apr-2023.pdf.</Citation></Reference><Reference><Citation>Wilkinson AL, Zaman K, Hoque M, et al., Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis 2023; 23(9):1062–1071 DOI: 10.1016/S1473-3099(23)00139-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00139-1</ArticleId><ArticleId IdType="pmc">PMC10503264</ArticleId><ArticleId IdType="pubmed">37178706</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Polio endgame complexity: updating expectations for nOPV2. Lancet Infect Dis 2023; 23(9):992–994 DOI: 10.1016/S1473-3099(23)00133-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00133-0</ArticleId><ArticleId IdType="pubmed">37178705</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner BG and Earn DJ, Circulating vaccine derived polio viruses and their impact on global polio eradication. Bull Math Biol 2008; 70(1):253–80 DOI: 10.1007/s11538-007-9255-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11538-007-9255-4</ArticleId><ArticleId IdType="pubmed">17934778</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis, 2015. 15, 389 DOI: 10.1186/s12879-015-1112-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1112-8</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al., Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis 2015; 211(11):1800–12 DOI: 10.1093/infdis/jiu674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu674</ArticleId><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, et al., Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis 2016; 16:137 DOI: 10.1186/s12879-016-1465-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1465-7</ArticleId><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Denes A and Szekely L, Global dynamics of a mathematical model for the possible re-emergence of polio. Math Biosci 2017; 293:64–74 DOI: 10.1016/j.mbs.2017.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mbs.2017.08.010</ArticleId><ArticleId IdType="pubmed">28859911</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson Costs KM and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. MDM Policy Pract, 2017. 2, 2381468317697002 DOI: 10.1177/2381468317697002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2381468317697002</ArticleId><ArticleId IdType="pmc">PMC6124926</ArticleId><ArticleId IdType="pubmed">30288417</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy KA, Chabot-Couture G, Famulare M, et al., The risk of type 2 oral polio vaccine use in post-cessation outbreak response. BMC Med 2017; 15(1):175 DOI: 10.1186/s12916-017-0937-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-017-0937-y</ArticleId><ArticleId IdType="pmc">PMC5627419</ArticleId><ArticleId IdType="pubmed">28974220</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Duintjer Tebbens RJ, Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis 2017; 216(suppl_1):S168-S175 DOI: 10.1093/infdis/jix128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix128</ArticleId><ArticleId IdType="pmc">PMC5853947</ArticleId><ArticleId IdType="pubmed">28838198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson KM, Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines 2018; 17(8):739–751 DOI: 10.1080/14760584.2018.1506333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1506333</ArticleId><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, et al., Updated characterization of outbreak response strategies for 2019–2029: Impacts of using a novel type 2 oral poliovirus vaccine strain. Risk Anal 2021; 41(2):329–348 DOI: 10.1111/risa.13622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13622</ArticleId><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Badizadegan K, Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Rev Vaccines 2021; 20(4):449–460 DOI: 10.1080/14760584.2021.1891889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1891889</ArticleId><ArticleId IdType="pubmed">33599178</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, and Badizadegan K, Health economic analysis of vaccine options for the polio eradication endgame: 2022–2036. Expert Rev Vaccines 2022; 21(11):1667–1674 DOI: 10.1080/14760584.2022.2128108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2128108</ArticleId><ArticleId IdType="pmc">PMC10116513</ArticleId><ArticleId IdType="pubmed">36154436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wiesen E, Wassilak SGF, et al., Worst-case scenarios: Modeling uncontrolled type 2 polio transmission. Risk Anal 2023; DOI: 10.1111/risa.14159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.14159</ArticleId><ArticleId IdType="pmc">PMC10733542</ArticleId><ArticleId IdType="pubmed">37344376</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. 2023. Polio immunisation response in London 2022 to 2023: information for healthcare practitioners
GOV.UK. (Accessed
Aug 11, 2023). Available from: https://www.gov.uk/government/publications/inactivated-polio-vaccine-ipv-booster-information-for-healthcare-practitioners/polio-immunisation-response-in-london-2022-to-2023-information-for-healthcare-practitioners.</Citation></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, Routh JA, et al. Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. Expert Review of Vaccines 2024; 23(1):186–195, doi:10.1080/14760584.2023.2299401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2299401</ArticleId><ArticleId IdType="pmc">PMC11284832</ArticleId><ArticleId IdType="pubmed">38164695</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman LM, Manor Y, Hindiyeh M, et al., Molecular Characterization of Polio from Environmental Samples: ISSP, The Israeli Sewage Surveillance Protocol. Methods Mol Biol 2016; 1387:55–107 DOI: 10.1007/978-1-4939-3292-4_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3292-4_5</ArticleId><ArticleId IdType="pubmed">26983731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Health Organization. 2013. WHO sends mission to Israel following detection of wild poliovirus in sewage.
Regional Office for the Americas of the World Health Organization
(Accessed
Aug 11, 2023). Available from: https://www3.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=8857:2013-who-sends-mission-israel-following-detection-wild-poliovirus-sewage&amp;Itemid=0&amp;lang=en#gsc.tab=0.</Citation></Reference><Reference><Citation>Yaari R, Kaliner E, Grotto I, et al., Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel. BMC Med 2016; 14(1):95 DOI: 10.1186/s12916-016-0637-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-016-0637-z</ArticleId><ArticleId IdType="pmc">PMC4918056</ArticleId><ArticleId IdType="pubmed">27334457</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis E, Kopel E, Singer SR, et al., Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill 2013; 18(38) DOI: 10.2807/1560-7917.es2013.18.38.20586.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es2013.18.38.20586</ArticleId><ArticleId IdType="pubmed">24084337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopel E, Kaliner E, and Grotto I, Lessons from a public health emergency - importation of wild poliovirus to Israel. N Engl J Med 2014; 371(11):981–3 DOI: 10.1056/NEJMp1406250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1406250</ArticleId><ArticleId IdType="pubmed">25207764</ArticleId></ArticleIdList></Reference><Reference><Citation>Chorin O, Markovich MP, Avramovich E, et al., Oral and fecal polio vaccine excretion following bOPV vaccination among Israeli infants. Vaccine 2023; 41(28):4144–4150 DOI: 10.1016/j.vaccine.2023.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.05.036</ArticleId><ArticleId IdType="pubmed">37268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyal NK, The right for autonomy, the duty of disclosure and public health considerations – The 2013 polio crisis in Israel as a case study. Pace Law Rev 2016; 36(3):908–969 DOI: 10.58948/2331-3528.1930.</Citation><ArticleIdList><ArticleId IdType="doi">10.58948/2331-3528.1930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamin-Friedman S, Would it be legally justified to impose vaccination in Israel? Examining the issue in light of the 2013 detection of polio in Israeli sewage. Isr J Health Policy Res 2017; 6(1):58 DOI: 10.1186/s13584-017-0182-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13584-017-0182-z</ArticleId><ArticleId IdType="pmc">PMC5661933</ArticleId><ArticleId IdType="pubmed">29084599</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevots DR, Burr RK, Sutter RW, et al., Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-5):1–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15580728</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Orenstein WA, and Hinman AR, Performance of the United States Vaccine Injury Compensation Program (VICP): 1988–2019. Vaccine 2020; 38(9):2136–2143 DOI: 10.1016/j.vaccine.2020.01.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.01.042</ArticleId><ArticleId IdType="pmc">PMC7853082</ArticleId><ArticleId IdType="pubmed">31982259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd S, Clark T, Routh J, et al., Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72(49):1327–1330 DOI: 10.15585/mmwr.mm7249a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7249a3</ArticleId><ArticleId IdType="pmc">PMC10715822</ArticleId><ArticleId IdType="pubmed">38060431</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>